Bicycle Therapeutics Plc
Research Bicycle Therapeutics Plc (BCYC) on Bullrun: market cap USD 289.72M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBCYC
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 289.72M
- Financial periodFY2025
- RevenueUSD 72.59M
- Revenue growth105.8%
- Net income-USD 218.96M
- Free cash flow-USD 252.03M
Valuation Snapshot
latest market cap is USD 289.72M.
About Bicycle Therapeutics Plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor;
Frequently asked questions
What is Bicycle Therapeutics Plc's market cap?
Bicycle Therapeutics Plc's market capitalization is USD 289.72M.
What does Bicycle Therapeutics Plc do?
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.